Cantor Fitzgerald Brokers Boost Earnings Estimates for ACAD

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of ACADIA Pharmaceuticals in a research report issued on Thursday, May 1st. Cantor Fitzgerald analyst C. Duncan now forecasts that the biopharmaceutical company will post earnings of $0.59 per share for the year, up from their prior estimate of $0.15. Cantor Fitzgerald currently has a “Overweight” rating and a $28.00 price target on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share.

Other research analysts have also recently issued research reports about the stock. UBS Group lowered their target price on shares of ACADIA Pharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, April 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Tuesday, April 8th. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. StockNews.com raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 8th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price objective for the company. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $23.87.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ:ACAD opened at $14.91 on Monday. The firm’s 50 day simple moving average is $16.14 and its two-hundred day simple moving average is $16.94. The company has a market capitalization of $2.49 billion, a P/E ratio of 19.12 and a beta of 0.47. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $20.68.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ACAD. CWM LLC increased its stake in ACADIA Pharmaceuticals by 50.1% in the 1st quarter. CWM LLC now owns 5,845 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 1,951 shares during the period. Louisiana State Employees Retirement System bought a new position in ACADIA Pharmaceuticals in the 1st quarter worth about $963,000. Mutual of America Capital Management LLC purchased a new position in shares of ACADIA Pharmaceuticals during the first quarter worth approximately $298,000. Xponance Inc. raised its stake in shares of ACADIA Pharmaceuticals by 14.1% during the first quarter. Xponance Inc. now owns 11,585 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 1,434 shares in the last quarter. Finally, Alps Advisors Inc. boosted its holdings in shares of ACADIA Pharmaceuticals by 4.2% in the first quarter. Alps Advisors Inc. now owns 140,225 shares of the biopharmaceutical company’s stock valued at $2,329,000 after purchasing an additional 5,681 shares during the period. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Insider Activity

In related news, Director Elizabeth A. Garofalo sold 4,919 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the sale, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. This represents a 21.85 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Mark C. Schneyer sold 2,708 shares of ACADIA Pharmaceuticals stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of $14.82, for a total transaction of $40,132.56. Following the transaction, the executive vice president now directly owns 59,456 shares of the company’s stock, valued at $881,137.92. The trade was a 4.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,994 shares of company stock worth $313,131. 28.30% of the stock is currently owned by corporate insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.